AOPPs inhibits cholesterol efflux by down-regulating ABCA1 expression in a JAK/STAT signaling pathway-dependent manner

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 9, 2011, Pages 796-807

  Mo, Zhong Cheng ^a   Xiao, Ji ^a   Liu, Xie Hong ^a   Hu, Yan Wei ^a   Li, Xiao Xu ^a   Yi, Guang Hui ^a   Wang, Zuo ^a   Tang, Ya Ling ^a   Liao, Duan Fang ^b   Tang, Chao Ke ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Advanced oxidation protein products; ATP binding cassette transporter A1; Cholesterol efflux; JAK STAT

Indexed keywords

ABC TRANSPORTER A1; ADVANCED OXIDATION PROTEIN PRODUCT; CHOLESTEROL; DIPHENYLIODONIUM SALT; JANUS KINASE; LIVER X RECEPTOR ALPHA; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; STAT PROTEIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; FOAM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; LIQUID SCINTILLATION COUNTING; MONOCYTE; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CHOLESTEROL; DOWN-REGULATION; HUMANS; JANUS KINASES; PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 80053217997     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.6569     Document Type: Article

References (46)

1. Ohashi R, Mu H, Wang X, Yao Q, Chen C: Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM, 2005; 98: 845-856
2. Oram JF, Heinecke JW: ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev, 2005; 85: 1343-1372
3. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet, 1999; 22: 347-351
4. Yokoyama S: ABCA1 and biogenesis of HDL. J Atheroscler Thromb, 2006; 13: 1-15
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int, 1996; 49: 1304-1313
6. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol, 1998; 161: 2524-2532
7. Skvarilova M, Bulava A, Stejskal D, Adamovska S, Bartek J: Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2005; 149: 83-87
8. Wykretowicz A, Adamska K, Krauze T, Guzik P, Szczepanik A, Rutkowska A, Wysoki H: The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults. Free Radic Res, 2007; 41: 645-649
9. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M: Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis, 2002; 162: 221-225
10. Selmeci L, Szekely M, Soos P, Seres L, Klinga N, Geiger A, Acsady G: Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res, 2006; 40: 952-958
11. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis, 2005; 45: 39-47
12. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene, 2002; 285: 1-24
13. Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci, 2004; 117: 1281-1283
14. Grote K, Luchtefeld M, Schieffer B: JANUS under stress--role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol, 2005; 43: 357-363
15. Liu SX, Hou FF, Guo ZJ, Nagai R, Zhang WR, Liu ZQ, Zhou ZM, Zhou M, Xie D, Wang GB, Zhang X: Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol, 2006; 26: 1156-1162
16. Marsche G, Heller R, Fauler G, Kovacevic A, Nuszkowski A, Graier W, Sattler W, Malle E: 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol, 2004; 24: 2302-2306
17. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, Descamps-Latscha B: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int, 2003; 64: 82-91
18. Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, Nagaraj RH, Xie D, Zhang X: Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal, 2008; 10: 1699-1712
19. Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S, Wadsack C, Scharnagl H, Stojakovic T, Heinemann A, Oettl K: Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res, 2009; 104: 750-757
20. Tang CK, Yi GH, Yang JH, Liu LS, Wang Z, Ruan CG, Yang YZ: Oxidized LDL upregulated ATP binding cassette transporter-1 in THP-1 macrophages. Acta Pharmacol Sin, 2004; 25: 581-586
21. Tang CK, Tang GH, Yi GH, Wang Z, Liu LS, Wan S, Yuan ZH, He XS, Yang JH, Ruan CG, Yang YZ: Effect of apolipoprotein A-I on ATP binding cassette transporter A1 degradation and cholesterol efflux in THP-1 macrophage-derived foam cells. Acta Biochim Biophys Sin (Shanghai), 2004; 36: 218-226
22. Zhang C, Yin W, Liao D, Huang L, Tang C, Tsutsumi K, Wang Z, Liu Y, Li Q, Hou H, Cai M, Xiao J: NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs. J Lipid Res, 2006; 47: 2055-2063
23. Tang CK, Yang JH, Yi GH, Wang Z, Liu LS, Wan ZY, Yuan ZH, Ruan CG, Yang YZ: [Effects of oleate on ATP binding cassette transporter A1 expression and cholesterol efflux in THP-1 macrophage-derived foam cells]. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 2003; 35: 1077-1082
24. Hu YW, Ma X, Li XX, Liu XH, Xiao J, Mo ZC, Xiang J, Liao DF, Tang CK: Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis, 2009; 204: e35-e43
25. Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, Liao DF, Xiang J, Tang CK: IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/ STAT signaling pathway-dependent manner. Atherosclerosis, 2009; 203: 417-428
26. Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, Li XX, Tang CK: The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/-mice. J Cardiovasc Pharmacol, 2008; 51: 467-475
27. Hu YW, Wang Q, Ma X, Li XX, Liu XH, Xiao J, Liao DF, Xiang J, Tang CK: TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophagederived foam cells. J Atheroscler Thromb, 2010; 17: 493-502
28. Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, Wilson JG, Willson TM, Collins JL, Kliewer SA: Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J Biol Chem, 2001; 276: 43509-43515
29. Kim TK, Maniatis T: Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science, 1996; 273: 1717-1719
30. Tanaka AR, Abe-Dohmae S, Ohnishi T, Aoki R, Morinaga G, Okuhira K, Ikeda Y, Kano F, Matsuo M, Kioka N, Amachi T, Murata M, Yokoyama S, Ueda K: Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. J Biol Chem, 2003; 278: 8815-8819
31. Brewer HB, Jr., Remaley AT, Neufeld EB, Basso F, Joyce C: Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of highdensity lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol, 2004; 24: 1755-1760
32. von Eckardstein A, Hersberger M, Rohrer L: Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care, 2005; 8: 147-152
33. Oram JF, Lawn RM: ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res, 2001; 42: 1173-1179
34. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR: Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol, 2003; 23: 1322-1332
35. Dai X, Ou X, Hao X, Cao D, Tang Y, Hu Y, Li X, Tang C: Effect of T0901317 on hepatic proinflammatory gene expression in apoE-/-mice fed a high-fat/high-cholesterol diet. Inflammation, 2007; 30: 105-117
36. Rane SG, Reddy EP: Janus kinases: components of multiple signaling pathways. Oncogene, 2000; 19: 5662-5679
37. Blanchette J, Jaramillo M, Olivier M: Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. Immunology, 2003; 108: 513-522
38. Martinez-Lostao L, Briones J, Forne I, Martinez-Gallo M, Ferrer B, Sierra J, Rodriguez-Sanchez JL, Juarez C: Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leuk Lymphoma, 2005; 46: 435-442
39. Bokoch GM, Knaus UG: NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci, 2003; 28: 502-508
40. Sabitha P, Vasudevan DM, Kamath P: Effect of high fat diet without cholesterol supplementation on oxidative stress and lipid peroxidation in New Zealand white rabbits. J Atheroscler Thromb, 2010; 17: 213-218
41. Kondo T, Hirose M, Kageyama K: Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb, 2009; 16: 532-538
42. Jo H, Song H, Mowbray A: Role of NADPH oxidases in disturbed flow-and BMP4-induced inflammation and atherosclerosis. Antioxid Redox Signal, 2006; 8: 1609-1619
43. Zalba G, Fortuno A, Orbe J, San Jose G, Moreno MU, Belzunce M, Rodriguez JA, Beloqui O, Paramo JA, Diez J: Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol, 2007; 27: 587-593
44. Simon AR, Rai U, Fanburg BL, Cochran BH: Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol, 1998; 275: C1640-1652
45. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H: Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res, 2000; 87: 1195-1201
46. Shi XY, Hou FF, Niu HX, Wang GB, Xie D, Guo ZJ, Zhou ZM, Yang F, Tian JW, Zhang X: Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology, 2008; 149: 1829-1839